MedTrace Logo

Phase 2 Study With SNF472 in Calciphylaxis Patients

NCT02790073 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-08-28

Study results available
· View outcomes & findings →

Summary

To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).

Conditions

  • Calciphylaxis
  • Calcific Uremic Arteriolopathy

Interventions

DRUG

SNF472

SNF472 for calciphylaxis

Sponsors & Collaborators

  • Sanifit Therapeutics S. A.

    lead OTHER

Principal Investigators

  • Vincent Brandenburg · RWTH Aachen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-11-15
Completion
2017-11-15

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02790073 on ClinicalTrials.gov